Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Grand Pharmaceutical Group Limited ( (HK:0512) ) has provided an update.
Grand Pharmaceutical Group Limited has secured a HK$0.8 billion term loan facility via its wholly owned subsidiary China Grand Pharmaceutical (HK) Limited, with the company and certain subsidiaries acting as guarantors. The loan has a 36‑month term, supporting the group’s financing flexibility and capital needs.
The facility agreement includes change‑of‑control covenants tied to controlling shareholders Mr. Hu Kaijun and Ms. Zhou Tong, allowing lenders to cancel commitments and demand immediate repayment if their combined beneficial ownership falls below 45% or rival voting control emerges. The company will provide ongoing disclosures while these conditions remain, highlighting creditor focus on ownership stability and governance risk for investors and stakeholders.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company engaged in the research, development, manufacturing and sale of pharmaceutical products. Through subsidiaries such as China Grand Pharmaceutical (HK) Limited, the group serves healthcare markets with a focus on prescription drugs and related medical treatments in Greater China and beyond.
Average Trading Volume: 4,718,631
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.38B
Learn more about 0512 stock on TipRanks’ Stock Analysis page.